Archimed
Biotech market provides dose of optimism
In the past year, the biotech market has seen buoyant activity, reaching record levels of investments
ArchiMed chair Ribon moves to New York office
ArchiMed also makes five new hires, including the appointment of BC Partners' Justin Bateman as partner
ArchiMed-backed Bomi bolts on Deco Pharma
With this add-on, the company plans to further strengthen its presence across southern Europe
ArchiMed acquires Zyto Group
ArchiMed has acquired a majority stake in Germany-based Zyto Group, a company that develops cancer diagnostic tests and equipment.
ArchiMed's Bomi bolts on Florence Shipping
Third add-on inked by Bomi, following its acquisition of Logifarma and its purchase of ILS
GP Profile: ArchiMed
Following the close of its new €1bn fund, ArchiMed's Denis Ribon discusses the firm's fundraising experience and investment pipeline
ArchiMed closes MED Platform I on €1bn
Oversubscribed fund closes above its €800m target after a couple of years on the road
ArchiMed's Bomi bolts on Logifarma
With the GP's support, Bomi intends to pursue an intensive buy-and-build strategy
Warburg Pincus invests in ArchiMed-backed Polyplus
ArchiMed and Warburg will be equal shareholders, while the management of Polyplus will retain a minority
How private equity is helping fight the Covid-19 outbreak
A round-up of initiatives by GPs across Europe – and their portfolio companies – to help their communities
NorthEdge sells DHG to ArchiMed for 3x return
During NorthEdge's holding period, the company made bolt-ons such as Nightingale, Kirton and Qbitus
ArchiMed appoints three new partners
Berthoux and Desmottes join as operating partners, while Philips becomes a strategic partner
Aksìa buys dental group Primo from Archimed
Sale ends a four-year holding period for French GP Archimed, which owned a 48% stake in the firm
ArchiMed-backed Micromed bolts on OSG
MicroMed has now made three acquisitions in the neurology diagnostics market with this acquisition
ArchiMed acquires Eurolyser and Eurolab
Transaction is part of a succession agreement that will see a co-founder of Eurolyser retire
French GPs opt for organic diversification
Recent fund closes show that organic diversification is still a valid option for some GPs and VCs willing to step out of their comfort zones
Sector specialisation taking hold in Europe
European private equity firms are sharpening their investment focus by restricting the number of sectors they target
